Amwell's Q1 2026: Profitability in Sight

Amwells Q1 2026 earnings show promising progress towards profitability. Despite an 18% revenue drop, subscription revenue stabilized and medical group visits surged by 9%. Gross margins remained steady at 51%, operating expenses decreased by 31%, and adjusted EBITDA loss narrowed significantly. The companys pipeline has tripled, with a focus on payer and government deals. Notable renewals include Elevance Health and the Defense Health Agency. Investors are optimistic due to strong visit growth, better renewals, and cost discipline. Amwell is well-positioned for multi-year growth, with guidance for Q2 revenue between $48-52 million and full-year revenue of $195-205 million. They aim for cash flow breakeven by Q4, supported by $179 million in cash and zero debt. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/6f8574273eea8be5